

Supplemental Table 1. Normal approximation to ACR20 response rates (SE) per visit

Month	Phase 3 studies				LTE study	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo to tofacitinib 5 mg BID	Placebo to tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
	% (SE) N					
1	56.74 (3.71) 178	64.41 (3.59) 177	35.42 (6.90) 48	37.21 (7.37) 43	68.63 (2.91) 255	82.4 (1.73) 483
3	68.93 (3.47) 177	75.72 (3.25) 173	40.00 (7.30) 45	30.95 (7.13) 42	76.52 (2.70) 247	84.02 (1.70) 463
6	79.17 (3.13) 168	79.27 (3.16) 164	63.64 (7.25) 44	60.53 (7.92) 38	72.53 (2.92) 233	84.25 (1.82) 400
9	71.72 (4.52) 99	84.21 (3.74) 95	82.61 (7.90) 23	81.82 (8.22) 22	74.78 (2.89) 226	79.14 (2.17) 350
12	79.79 (4.14) 94	83.52 (3.88) 91	73.91 (9.15) 23	72.73 (9.49) 22	77.67 (2.84) 215	81.29 (2.16) 326
15	n/a	n/a	n/a	n/a	79.02 (2.84) 205	76.09 (2.47) 297
18	n/a	n/a	n/a	n/a	79.10 (2.87) 201	73.89 (2.92) 226
21	n/a	n/a	n/a	n/a	76.60 (3.09) 188	80.43 (2.92) 184
24	n/a	n/a	n/a	n/a	85.39 (2.65) 178	78.66 (3.20) 164
27	n/a	n/a	n/a	n/a	81.66 (2.98) 169	81.25 (3.45) 128
30	n/a	n/a	n/a	n/a	82.82 (2.95) 163	76.54 (4.71) 81

Supplemental Table 1. Normal approximation to ACR20 response rates (SE) per visit

33	n/a	n/a	n/a	n/a	83.02 (2.98)	81.08 (4.55)
					159	74
36	n/a	n/a	n/a	n/a	83.87 (2.95)	74.29 (7.39)
					155	35

Full analysis set, no imputation.

American College of Rheumatology (ACR), Twice daily (BID), Long-term extension (LTE), Not available (n/a), Standard error (SE).

Supplemental Table 2. Normal approximation to ACR50 response rates (SE) per visit

	% (SE) N	Phase 3 studies			LTE study		
		Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo to tofacitinib 5 mg BID	Placebo to tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
Month							
1	23.6 (3.18)	31.07	10.42	6.98	46.67	57.97	
	178	(3.47) 177	(4.40) 48	(3.88) 43	(3.12) 255	(2.25) 483	
3	45.76	49.71	22.22	19.05	57.89	63.50	
	(3.74)	(3.80) 173	(6.19) 45	(6.05) 42	(3.14) 247	(2.24) 463	
6	52.98	59.15	43.18	34.21	55.79	61.00	
	(3.85)	(3.83) 164	(7.46) 44	(7.69) 38	(3.25) 233	(2.44) 400	
9	53.54	63.16	56.52	63.64	59.73	60.29	
	(5.01)	(4.94) 95	(10.33) 23	(10.25) 22	(3.26) 226	(2.62) 350	
12	52.13	60.44	56.52	50.00	56.74	58.90	
	(5.15) 94	(5.12) 91	(10.33) 23	(10.66) 22	(3.38) 215	(2.73) 326	
15	n/a	n/a	n/a	n/a	61.46	56.90	
					(3.40) 205	(2.87) 297	
18	n/a	n/a	n/a	n/a	58.21	58.41	
					(3.48) 201	(3.28) 226	
21	n/a	n/a	n/a	n/a	59.04	65.76	
					(3.59) 188	(3.50) 184	
24	n/a	n/a	n/a	n/a	65.73	59.76	
					(3.56) 178	(3.83) 164	
27	n/a	n/a	n/a	n/a	63.31	63.28	
					(3.71) 169	(4.26) 128	
30	n/a	n/a	n/a	n/a	66.87	62.96	
					(3.69) 163	(5.37) 81	
33	n/a	n/a	n/a	n/a	59.75	60.81	
					(3.89) 159	(5.67) 74	

Supplemental Table 2. Normal approximation to ACR50 response rates (SE) per visit

36	n/a	n/a	n/a	n/a	67.74 (3.75) 155	54.29 (8.42) 35
----	-----	-----	-----	-----	------------------------	-----------------------

Full analysis set, no imputation.

American College of Rheumatology (ACR), Twice daily (BID), Long-term extension

(LTE), Not available (n/a), Standard error (SE).

Supplemental Table 3. Normal approximation to ACR70 response rates (SE) per visit

% (SE) N	Phase 3 studies				LTE study	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo to tofacitinib 5 mg BID	Placebo to tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
Month						
1	6.18 (1.80) 178	9.60 (2.21) 177	4.17 (2.88) 48	2.33 (2.29) 43	27.06 (2.78) 255	34.58 (2.16) 483
3	17.51 (2.85) 177	23.12 (3.20) 173	8.89 (4.24) 45	4.76 (3.28) 42	36.84 (3.07) 247	37.15 (2.25) 463
6	27.38 (3.44) 168	31.71 (3.63) 164	13.64 (5.17) 44	18.42 (6.28) 38	36.05 (3.15) 233	37.25 (2.42) 400
9	31.31 (4.66) 99	36.84 (4.94) 95	26.09 (9.15) 23	31.82 (9.93) 22	39.38 (3.25) 226	39.14 (2.61) 350
12	35.11 (4.92) 94	40.66 (5.14) 91	21.74 (8.60) 23	27.27 (9.49) 22	35.81 (3.27) 215	40.18 (2.72) 326
15	n/a	n/a	n/a	n/a	39.02 (3.41) 205	40.40 (2.85) 297
18	n/a	n/a	n/a	n/a	38.31 (3.43) 201	38.50 (3.24) 226
21	n/a	n/a	n/a	n/a	40.96 (3.59) 188	41.30 (3.63) 184
24	n/a	n/a	n/a	n/a	42.70 (3.71) 178	39.63 (3.82) 164
27	n/a	n/a	n/a	n/a	42.01 (3.80) 169	42.19 (4.37) 128
30	n/a	n/a	n/a	n/a	42.33 (3.87) 163	44.44 (5.52) 81
33	n/a	n/a	n/a	n/a	38.99 (3.87)	39.19 (5.67)

159 74

Supplemental Table 3. Normal approximation to ACR70 response rates (SE) per visit

36	n/a	n/a	n/a	n/a	45.81 (4.00) 155	34.29 (8.02) 35
----	-----	-----	-----	-----	------------------------	-----------------------

Full analysis set, no imputation.

American College of Rheumatology (ACR), Twice daily (BID), Long-term extension (LTE), Not available (n/a), Standard error (SE).

Supplemental Table 4. Descriptive statistics of mean DAS28-4(ESR) score (SE) per visit

DAS28-4(ESR) score (SE) N	Phase 3 studies				LTE study	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo to tofacitinib 5 mg BID	Placebo to tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
Month						
Baseline	6.60 (0.08) 180	6.49 (0.09) 170	6.70 (0.14) 47	6.77 (0.12) 46	6.19 (0.07) 230	6.57 (0.05) 483
1	5.07 (0.18) 58	4.74 (0.18) 60	6.05 (0.42) 15	5.00 (0.42) 13	3.83 (0.09) 239	3.70 (0.06) 471
3	4.33 (0.10) 165	4.11 (0.10) 163	5.33 (0.24) 43	5.28 (0.21) 40	3.69 (0.09) 233	3.50 (0.06) 455
6	4.04 (0.10) 151	3.83 (0.11) 155	4.25 (0.21) 42	4.37 (0.27) 35	3.68 (0.09) 219	3.54 (0.06) 391
9	4.30 (0.16) 57	3.82 (0.16) 56	3.81 (0.40) 13	4.29 (0.44) 12	3.58 (0.09) 211	3.56 (0.07) 342
12	3.89 (0.13) 80	3.59 (0.14) 84	4.27 (0.31) 21	4.22 (0.23) 20	3.65 (0.09) 203	3.56 (0.07) 318
15	n/a	n/a	n/a	n/a	3.58 (0.09) 192	3.53 (0.07) 284
18	n/a	n/a	n/a	n/a	3.62 (0.09) 187	3.55 (0.09) 216
21	n/a	n/a	n/a	n/a	3.60 (0.09) 175	3.51 (0.09) 178
24	n/a	n/a	n/a	n/a	3.59 (0.09) 167	3.67 (0.11) 157

Supplemental Table 4. Descriptive statistics of mean DAS28-4(ESR) score (SE) per visit

27	n/a	n/a	n/a	n/a	3.57 (0.09) 156	3.55 (0.11) 126
30	n/a	n/a	n/a	n/a	3.53 (0.10) 151	3.66 (0.15) 80
33	n/a	n/a	n/a	n/a	3.62 (0.09) 148	3.88 (0.16) 72
36	n/a	n/a	n/a	n/a	3.41 (0.10) 142	3.85 (0.24) 34

Full analysis set, no imputation.

Twice daily (BID), Disease activity score (28 joints) (DAS28), Erythrocyte sedimentation rate (ESR), Long-term extension (LTE), Not available (n/a), Standard error (SE).

Supplemental Table 5. Descriptive statistics of mean change from baseline (SE) in

HAQ-DI per visit

Change from baseline in HAQ-DI (SE) N	Phase 3 studies				LTE study	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo to tofacitinib 5 mg BID	Placebo to tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
Month						
1	-0.43	-0.63	-0.22	-0.20	-0.64	-0.80
	(0.04)	(0.04)	(0.06)	(0.06)	(0.05)	(0.03)
	178	177	48	43	246	475
3	-0.62	-0.76	-0.34	-0.31	-0.66	-0.82
	(0.05)	(0.05)	(0.09)	(0.08)	(0.04)	(0.03)
	177	173	45	42	236	456
6	-0.73	-0.84	-0.48	-0.46	-0.63	-0.78
	(0.05)	(0.05)	(0.09)	(0.11)	(0.05)	(0.04)
	168	164	44	38	224	393
9	-0.76	-0.97	-0.64	-0.60	-0.63	-0.76
	(0.07)	(0.07)	(0.13)	(0.13)	(0.05)	(0.04)
	99	95	23	22	216	345
12	-0.71	-0.91	-0.77	-0.53	-0.68	-0.73
	(0.07)	(0.07)	(0.15)	(0.13)	(0.05)	(0.04)
	94	91	23	22	208	319
15	n/a	n/a	n/a	n/a	-0.64	-0.75
					(0.05)	(0.04)
					199	284

Supplemental Table 5. Descriptive statistics of mean change from baseline (SE) in HAQ-

DI per visit

18	n/a	n/a	n/a	n/a	-0.65	-0.75
					(0.05)	(0.05)
					194	220
21	n/a	n/a	n/a	n/a	-0.68	-0.81
					(0.06)	(0.05)
					183	179

					-0.69	-0.80
24	n/a	n/a	n/a	n/a	(0.05)	(0.06)
					174	160
					-0.68	-0.86
27	n/a	n/a	n/a	n/a	(0.05)	(0.07)
					165	125
					-0.68	-0.80
30	n/a	n/a	n/a	n/a	(0.06)	(0.08)
					159	79
					-0.69	-0.77
33	n/a	n/a	n/a	n/a	(0.06)	(0.08)
					155	73
					-0.75	-0.73
36	n/a	n/a	n/a	n/a	(0.06)	(0.13)
					150	33

Full analysis set, no imputation.

Twice daily (BID), Disease activity score (28 joints) (DAS28), Erythrocyte sedimentation rate (ESR), Long-term extension (LTE), Not available (n/a), Standard error (SE).